Kairos Pharma
KAPA
14 hedge funds and large institutions have $506K invested in Kairos Pharma in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
193% more capital invested
Capital invested by funds: $173K → $506K (+$333K)
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
40% more funds holding
Funds holding: 10 → 14 (+4)
0.85% more ownership
Funds ownership: 1.3% → 2.15% (+0.85%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$151K |
| 2 |
Two Sigma Investments
New York
|
+$52.3K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$50.3K |
| 4 |
State Street
Boston,
Massachusetts
|
+$27.5K |
| 5 |
FIA
FNY Investment Advisers
New York
|
+$26.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$57.5K |
| 2 |
HF
HRT Financial
New York
|
-$9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.98K |
| 4 |
Citigroup
New York
|
-$3.9K |
KAPA Hedge Fund Activity: Q3 2025 in Review
14 of the 7,645 institutional investors tracked by Wall St. Rank reported a position in Kairos Pharma (KAPA) for Q3 2025, worth a combined $506K — up 193% from $173K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new KAPA positions and 2 closed out — a net gain of 4 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $151K. The largest seller was XTX Topco, cutting an estimated $57.5K.
- 14 institutional investors held Kairos Pharma (KAPA) as of Q3 2025, up from 10 in Q2 2025.
- Funds reported $506K of Kairos Pharma stock for Q3 2025, up 193% quarter-over-quarter.
- 6 funds opened new Kairos Pharma positions in Q3 2025 and 2 closed out, a net change of +4 holders.
- The largest Kairos Pharma buyer in Q3 2025 was Vanguard Group, an estimated $151K added.
- The largest Kairos Pharma seller in Q3 2025 was XTX Topco, an estimated $57.5K sold.
Based on aggregated 13F filings for Q3 2025.